메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
박지현 (한국화이자제약) 정재홍 (한국화이자제약) 황성혜 (한국화이자제약)
저널정보
한국보건의료기술평가학회 보건의료기술평가 보건의료기술평가 제3권 제2호
발행연도
2015.12
수록면
99 - 106 (8page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is considered to be the primary cause of hospital acquired pneumonia (HAP) and MRSA-associated HAP occur a significant impact on healthcare resource use and associated economic costs. The objective of this study was to investigate the economic impact of linezolid compared with that of vancomycin in the treatment of hospitalized pa- tients with MRSA-confirmed HAP in the Korea. Methods: A 30-days decision tree model incorporat- ed published data on clinical parameters, resource use, and costs were constructed. The base case first- line treatment duration for patients with hospital-acquired pneumonia was 10 days. Treatment success, discontinuation due to adverse events, discontinuation due to lack of efficacy, and mortality were possi- ble outcomes that could impact costs. Results: The model calculated that linezolid was associated with an 1.8% higher cure rate compared with vancomycin (62.5% vs. 60.7%, respectively). Average total costs per episode for linezolid-and vancomycin-treated patients were KRW 3420971 and 3459977 respective- ly. The incremental cost-effectiveness ratio favored linezolid (versus vancomycin), with marginally low- er costs (by KRW 39006) and greater efficacy (+1.8% absolute difference in the proportion of patients successfully treated for MRSA HAP). Conclusion: The study shows that linezolid is a cost-effective al- ternative to vancomycin for HAP.

목차

등록된 정보가 없습니다.

참고문헌 (20)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0